PRETREATMENT WITH DIVIDED DOSES OF STEROIDS STRONGLY DECREASES SIDE-EFFECTS OF OKT3

被引:14
作者
BEMELMAN, FJ
BUYSMANN, S
SURACHNO, J
WILMINK, JM
SCHELLEKENS, PTA
TENBERGE, IJM
机构
[1] UNIV AMSTERDAM,ACAD MED CTR,DEPT INTERNAL MED,RENAL TRANSPLANT UNIT F4 215,1100 DE AMSTERDAM,NETHERLANDS
[2] UNIV AMSTERDAM,ACAD MED CTR,CLIN IMMUNOL UNIT,1100 DE AMSTERDAM,NETHERLANDS
关键词
D O I
10.1038/ki.1994.467
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The aim of this study was to attenuate side effects of OKT3 by variation of the time interval between administration of corticosteroids and OKT3 in renal allograft recipients. In view of a maximal lymphocytopenia at six hours following MPNS, we postulated a greater preventive action on side effects from administration of methylprednisolone (MPNS) at six hours preceding the first dose of OKT3 compared to administration immediately before. Two groups of renal transplant patients treated for acute rejection with 5 mg OKT3 were studied. Ten patients received 500 mg MPNS six hours and ten patients one hour before administration of OKT3. We measured clinical side effects, body temperature, TNF and IL-6. There were no differences between the two groups regarding clinical side effects and peak body temperatures. However, MPNS administered six hours before administration of OKT3 diminished TNF release; MPNS one hour before decreased IL-6 release. We studied an additional group of six patients receiving 250 mg MPNS six hours before, followed by 250 mg one hour before OKT3. This group experienced significantly less side effects and lower body temperature. In addition, IL-6 levels were significantly decreased. We conclude that two times 250 mg MPNS administered six hours and one hour before the first administration of OKT3 effectively attenuates adverse reactions following administration of OKT3.
引用
收藏
页码:1674 / 1679
页数:6
相关论文
共 36 条
  • [1] RELEASE OF TUMOR NECROSIS FACTOR, INTERLEUKIN-2, AND GAMMA-INTERFERON IN SERUM AFTER INJECTION OF OKT3 MONOCLONAL-ANTIBODY IN KIDNEY-TRANSPLANT RECIPIENTS
    ABRAMOWICZ, D
    SCHANDENE, L
    GOLDMAN, M
    CRUSIAUX, A
    VEREERSTRAETEN, P
    DEPAUW, L
    WYBRAN, J
    KINNAERT, P
    DUPONT, E
    TOUSSAINT, C
    [J]. TRANSPLANTATION, 1989, 47 (04) : 606 - 608
  • [2] EVIDENCE THAT PENTOXIFYLLINE REDUCES ANTI-CD3 MONOCLONAL ANTIBODY-INDUCED CYTOKINE RELEASE SYNDROME
    ALEGRE, ML
    GASTALDELLO, K
    ABRAMOWICZ, D
    KINNAERT, P
    VEREERSTRAETEN, P
    DEPAUW, L
    VANDENABEELE, P
    MOSER, M
    LEO, O
    GOLDMAN, M
    [J]. TRANSPLANTATION, 1991, 52 (04) : 674 - 679
  • [3] ALEGRE ML, 1991, J IMMUNOL, V146, P1184
  • [4] BARBER AE, 1993, J IMMUNOL, V150, P1999
  • [5] CONTROL OF CACHECTIN (TUMOR-NECROSIS-FACTOR) SYNTHESIS - MECHANISMS OF ENDOTOXIN RESISTANCE
    BEUTLER, B
    KROCHIN, N
    MILSARK, IW
    LUEDKE, C
    CERAMI, A
    [J]. SCIENCE, 1986, 232 (4753) : 977 - 980
  • [6] BLOEMENA E, 1990, TRANSPLANTATION, V50, P330
  • [7] ENCEPHALOPATHY ASSOCIATED WITH OKT3 ADMINISTRATION - POSSIBLE INTERACTION WITH INDOMETHACIN
    CHAN, GL
    WEINSTEIN, SS
    WRIGHT, CE
    BOWERS, VD
    ALVERANGA, DY
    SHIRES, DL
    ACKERMANN, JR
    LEFOR, WW
    KAHANA, L
    [J]. TRANSPLANTATION, 1991, 52 (01) : 148 - 150
  • [8] EVIDENCE THAT ANTIHUMAN TUMOR-NECROSIS-FACTOR MONOCLONAL-ANTIBODY PREVENTS OKT3-INDUCED ACUTE SYNDROME
    CHARPENTIER, B
    HIESSE, C
    LANTZ, O
    FERRAN, C
    STEPHENS, S
    OSHAUGNESSY, D
    BODMER, M
    BENOIT, G
    BACH, JF
    CHATENOUD, L
    [J]. TRANSPLANTATION, 1992, 54 (06) : 997 - 1002
  • [9] CHATENOUD L, 1989, NEW ENGL J MED, V320, P1420
  • [10] CORTICOSTEROID INHIBITION OF THE OKT3-INDUCED CYTOKINE-RELATED SYNDROME - DOSAGE AND KINETICS PREREQUISITES
    CHATENOUD, L
    LEGENDRE, C
    FERRAN, C
    BACH, JF
    KREIS, H
    [J]. TRANSPLANTATION, 1991, 51 (02) : 334 - 338